Drugs / TAC01-CLDN18.2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05862324 | Aug 2023 → Aug 2027 expected | metastatic neoplasm | Triumvira Immunologics, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-11-11 | Triumvira Immunologics, Inc. | Results Triumvira Immunologics’ Late-Breaking Abstract Selected for Oral Presentation at the 39th SITC Annual Meeting Demonstrates Preliminary Safety and Promising Clinical Activity of TAC01-CLDN18.2 Cell Therapy in Patients with Solid Tumors triumvira.com ↗ |
| 2024-10-15 | Triumvira Immunologics, Inc. | Results Triumvira Immunologics Announces Publication Demonstrating the Safety and Efficacy of TAC T Cells Targeting Claudin 18.2 in Solid Tumors triumvira.com ↗
The article, authored by a team of scientists led by Dr. Andreas Bader , Triumvira’s Consulting Chief Scientific Officer, details the preclinical pharmacology and safety of TAC01-CLDN18.2, a novel autologous T cell therapy targeting Claudin 18.2 for the treatment of solid tumors. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-11-11 | Triumvira Immunologics, Inc. | Triumvira Immunologics’ Late-Breaking Abstract Selected for Oral Presentation at the 39th SITC Annual Meeting Demonstrates Preliminary Safety and Promising Clinical Activity of TAC01-CLDN18.2 Cell Therapy in Patients with Solid Tumors triumvira.com ↗ |
| 2024-10-15 | Triumvira Immunologics, Inc. | Triumvira Immunologics Announces Publication Demonstrating the Safety and Efficacy of TAC T Cells Targeting Claudin 18.2 in Solid Tumors triumvira.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAC01-CLDN18.2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05862324 ↗ |
| Action | Deplete | “where the protein expression is no longer limited to tight junctions and are visible to T cells to eradicate them.” NCT05862324 ↗ |
| Modality | Cell therapy | “TAC01-CLDN18.2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes Claudin 18.2.” NCT05862324 ↗ |
| Route | Intravenous | “Lymphodepletion followed by TAC01-CLDN18.2 as a single IV infusion.” NCT05862324 ↗ |
| Target | CLDN18 | “TAC T cells recognize the CLDN18.2, a tight junction protein present on the surface of tumor cells” NCT05862324 ↗ |